Grace Capital’s AbbVie ABBV Stock Holding History

Grace Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$379K	Buy	2,800 +600	+27%	+$70.9K	0.23%	104
2021 Q3	$239K	Buy	2,200 +800	+57%	+$91.4K	0.15%	131
2021 Q2	$158K	Sell	1,400 -1,400	-50%	-$158K	0.11%	144
2021 Q1	$303K	Hold	2,800	–	–	0.19%	128
2020 Q4	$300K	Sell	2,800 -700	-20%	-$67.3K	0.19%	123
2020 Q3	$306K	Hold	3,500	–	–	0.24%	99
2020 Q2	$344K	Buy	3,500 +200	+6%	+$17.6K	0.3%	91
2020 Q1	$251K	Buy	3,300 +300	+10%	+$25.6K	0.25%	95
2019 Q4	$266K	Sell	3,000 -1,600	-35%	-$133K	0.22%	109
2019 Q3	$348K	Sell	4,600 -500	-10%	-$34.3K	0.35%	80
2019 Q2	$371K	Hold	5,100	–	–	0.18%	123
2019 Q1	$411K	Sell	5,100 -400	-7%	-$32.7K	0.16%	138
2018 Q4	$507K	Buy	5,500 +2,500	+83%	+$220K	0.24%	113
2018 Q3	$284K	Sell	3,000 -1,500	-33%	-$142K	0.11%	140
2018 Q2	$417K	Buy	+4,500	New	+$439K	0.16%	124

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Grace Capital's ABBV Position: Q4 2021 in Review

Grace Capital increased its AbbVie (ABBV) stake by 27% in Q4 2021, buying an estimated $70.9K and bringing the position to 2,800 shares worth $379K. The position accounts for 0.23% of the portfolio, ranked #104.

Grace Capital first reported a position in ABBV in Q2 2018 and has held it in 15 quarters since. The position peaked at $507K in Q4 2018. 2,981 funds tracked by Wall St. Rank hold ABBV as of Q4 2021.

Grace Capital held 2,800 shares of AbbVie worth $379K as of Q4 2021.
Grace Capital bought 600 AbbVie shares in Q4 2021, an estimated $70.9K.
AbbVie made up 0.23% of Grace Capital's portfolio in Q4 2021, its #104 holding.
Grace Capital first reported a position in AbbVie in Q2 2018 and has held it in 15 quarters since.
Grace Capital's AbbVie position peaked at $507K in Q4 2018.
2,981 funds tracked by Wall St. Rank held AbbVie as of Q4 2021.

Based on Grace Capital's 13F filing for Q4 2021, filed 2 Feb 2022.